Recruiting
Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy
About this study
The aim of this randomized study is to investigate pneumonitis, local tumor control, and survival outcomes of primary tumor radiotherapy omitting CTV for patients with advanced NSCLC responded to immunotherapy and chemotherapy
- Condition
- Advanced Non-Small Cell Squamous Lung Cancer, Radiotherapy, Immunotherapy
- Tested
- CTV omitted or delineated
- Sponsor
- Hubei Cancer Hospital
Who can join
- Age
- 18 to 75 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 9
- Minimum age: 18 years
- Maximum age: 75 years
- Study condition: Advanced Non-Small Cell Squamous Lung Cancer, Radiotherapy, Immunotherapy
- Histologically or cytologically confirmed advanced non-small cell lung cancer (according to the 8th edition of the TNM cancer staging system of AJCC and UICC);
- After over two cycles of chemotherapy combined with immunotherapy, the efficacy was CR, PR or SD (with a decreasing trend);
- Age 18 to 80 years old, performance status 0-1;
- measurable or evaluable lesions;
- Survival expectancy is not less than 6 months;
- adequate cardiac, pulmonary, renal, and hepatic and bone marrow function
Exclusion 10
- tumor progress after therapy with immunotherapy and chemotherapy
- EGFR, ALK, or ROS1 mutation;
- Previous thoracic radiotherapy;
- grade 2 or more immune-related adverse events after induction immunotherapy
- Previous malignancies (except stage I non-melanic skin cancer or cervical carcinoma in situ);
- Pregnant or lactating women
- undergoing other clinical trials;
- Have serious comorbidities, including myocardial infarction, severe arrhythmia, severe cerebrovascular disease, ulcer disease, psychosis and uncontrollable diabetes;
- Patients with HIV positive and undergoing antiviral therapy;
- Active tuberculosis
Where
1 site, 1 recruiting
Hubei Cancer Hospital
Wuhan, Hubei, China
Contact
-
Guang Han, PhD
+86 13886048178 hg7913@hotmail.com
Potential match only. Final eligibility is determined by the study team.